Abstract:OBJECTIVETo evaluate the efficacy and safety of standard term (12 months) or long term (> 12 months) dual antiplatelet therapy (DAPT) versus short term (< 6 months) DAPT after percutaneous coronary intervention (PCI) with drug-eluting stent (DES).DESIGNSystematic review and network meta-analysis.DATA SOURCESRelevant studies published between June 1983 and April 2018 from Medline, Embase, Cochrane Library for clinical trials, PubMed, Web of Science, ClinicalTrials.gov, and Clinicaltrialsregister.eu.REVIEW METHODSRandomised controlled trials comparing two of the three durations of DAPT (short term, standard term, and long term) after PCI with DES were included. The primary study outcomes were cardiac or non-cardiac death, all cause mortality, myocardial infarction, stent thrombosis, and all bleeding events.RESULTS17 studies (n=46 864) were included. Compared with short term DAPT, network meta-analysis showed that long term DAPT resulted in higher rates of major bleeding (odds ratio 1.78, 95% confidence interval 1.27 to 2.49) and non-cardiac death (1.63, 1.03 to 2.59); standard term DAPT was associated with higher rates of any bleeding (1.39, 1.01 to 1.92). No noticeable difference was observed in other primary endpoints. The sensitivity analysis revealed that the risks of non-cardiac death and bleeding were further increased for >= 18 months of DAPT compared with short term or standard term DAPT. In the subgroup analysis, long term DAPT led to higher all cause mortality than short term DAPT in patients implanted with newer-generation DES (1.99, 1.04 to 3.81); short term DAPT presented similar efficacy and safety to standard term DAPT with acute coronary syndrome (ACS) presentation and newer-generation DES placement. The heterogeneity of pooled trials was low, providing more confidence in the interpretation of results.CONCLUSIONSIn patients with all clinical presentations, compared with short term DAPT (clopidogrel), long term DAPT led to higher rates of major bleeding and non-cardiac death, and standard term DAPT was associated with an increased risk of any bleeding. For patients with ACS, short term DAPT presented similar efficacy and safety with standard term DAPT. For patients implanted with newer-generation DES, long term DAPT resulted in more all cause mortality than short term DAPT. Although the optimal duration of DAPT should take personal ischaemic and bleeding risks into account, this study suggested short term DAPT could be considered for most patients after PCI with DES, combining evidence from both direct and indirect comparisons.SYSTEMATIC REVIEW REGISTRATIONPROSPERO CRD42018099519.

The follow-up study of dual antiplatelet therapy (DAPT) duration and the prognosis of coronary heart diseases patients after drug-eluting stent (DES) implantation

Prolonged Dual Antiplatelet Therapy in Acute Myocardial Infarction Patients Without Revascularization: China Acute Myocardial Infarction Registry Study.

Duration of Dual Antiplatelet Therapy after Implantation of the First-Generation and Second-Generation Drug-Eluting Stents

Comparative Efficacy and Safety of Duration of Dual Antiplatelet Therapy in Patients with CAD Undergoing Drug-eluting Stent Implantation: A Systematic Review and Network Meta-analysis.

Novel insights on dual antiplatelet therapy duration following stenting for angiography-detected moderate-to-severe calcified coronary lesions

Optimize the Duration of DAPT Following DES Implantation: an Updated System Review and Meta-Analysis of 10 Randomized Trials

Duration Of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention With Drug-Eluting Stent: Systematic Review And Network Meta-Analysis

Meta Analysis of Dual Antiplatelet Therapy≤6 Months and Dual Antiplatelet Therapy≥12 Months in Patients After Drug-eluting Stent Implantation

Clinical outcomes of dual antiplatelet therapy after implantation of drug-eluting stents in patients with different cardiovascular risk factors

Optimal duration of dual-antiplatelet therapy following drug-eluting stent implantation: a meta-analysis.

Duration of dual antiplatelet therapy after percutaneous coronary intervention with implantation of second-generation drug-eluting stent: A meta-analysis of randomized controlled trials.

Meta analysis of different durations of dual anti-platelet therapy after percutaneous coronary intervention with drug eluting stents in patients with coronary disease

Dual antiplatelet therapy over 6 months increases the risk of bleeding after biodegradable polymer-coated sirolimus eluting stents implantation: insights from the CREATE study.

The Importance of the Mean Platelet Aggregation Degree in Long-term Dual Antiplatelet Therapy Following Drug Eluting Stent Implantation.

Short-term (1–3 months) versus standard (12 months) dual antiplatelet therapy following new-generation drug-eluting stent implantation: A meta-analysis of randomized controlled trials

Prolonging Dual Antiplatelet Therapy Improves Long-term Prognosis in Diabetic Patients Undergoing Complex Percutaneous Coronary Intervention with Drug-eluting Stents

Efficacy and Safety of Dual Antiplatelet Therapy in Patients Undergoing Coronary Stent Implantation: A Systematic Review and Network Meta-Analysis

Rationale and Design of Dual Antiplatelet Therapy in Patients with Coronary Multi‐Vessel Disease (DAPT‐MVD): A Multicenter, Randomized, Controlled Trial

Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and …

Shorter (≤6 Months) Vs. Longer (≥12 Months) Dual Antiplatelet Therapy after Second-Generation Drug-Eluting Stents Implantation: a Meta-Analysis of Randomized Controlled Trials

Dual antiplatelet therapy after percutaneous coronary intervention in patients at high bleeding risk: A systematic review and meta-analysis